A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss

Community Outreach Support and Engagement Using Online Strategies - Decentralized Insights Into Therapy Adoption and Value

This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active community of people using anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of participants to engage in a digital study, provide consent, and complete various study-related tasks, including a self-collected capillary blood sample for assay testing and health related surveys.

Inclusion Criteria:

• Adults 18 - 80 years of age.
• Living in the United States.
• Consented from the Inspire online platform patient community for COSMOS-DIGITAL.
• Self-Reported current use of, and intention to continue for at least 30 days, one of the following medications for the indications of weight management/obesity:
• Semaglutide (wegovy)
• Tirzepatide (zepbound)

Exclusion Criteria:

• Currently receiving treatment in another investigational device or drug study, or participation in a current clinical trial.
• Self-reported sensitivity/allergy to any of the components of the self-draw collection device including stainless steel or elements commonly found in stainless steel.
• Self-reported fear of blood.
• Self-reported circulatory conditions causing difficulty in drawing capillary blood.
• Known history of bleeding diathesis or any coagulation disorder.
• History of skin disorders, abnormal skin integrity or atypical skin health within the areas to be tested in the upper arm.